Duloxetine (Cymbalta®) has been granted a licence extension to include diabetic peripheral neuropathic pain in adults.
The Scottish Medicines Consortium have reviewed the use of duloxetine for this condition and recommended that use is restricted. They have recommended that treatment is initiated by prescribers who are experienced in the management of diabetic peripheral neuropathic pain as a second or third line therapy option.
Action: Duloxetine is not a first line treatment and may only be appropriate for initiation in secondary care settings.
|« Yearly Bisphosphonate!||Contraceptive patch and VTE warning »|